Torcitabine is an experimental antiviral agent primarily investigated for its potential in treating hepatitis B virus (HBV) infections. It functions as a nucleoside analog, interfering with viral DNA synthesis by inhibiting the HBV polymerase enzyme, which is essential for viral replication. Due to its targeted mechanism, Torcitabine has shown promise in reducing viral load in preclinical studies. It is being explored for use in chronic hepatitis B, especially in cases where current therapies have limited efficacy or resistance has developed. Research is ongoing to evaluate its safety, bioavailability, and long-term therapeutic benefits.